Recro Pharma Total Liabilities

Recro Pharma (REPH) currently reports a total liabilities of $95M as of December 2023. That compares with $98M in the prior-year period — down 2.8% year over year. Use the charts on this page to explore Recro Pharma's total liabilities history and peer comparisons.

Recro Pharma's total liabilities decreased from $98M to $95M — a 2.8% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Recro Pharma reported $95M in total liabilities as of December 2023. That compares with $98M in the prior-year period — down 2.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $95M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Recro Pharma, and consider following REPH for alerts when major investors trade the stock.

Recro Pharma is classified in the Healthcare sector. On total liabilities, it currently shows $95M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing REPH with unrelated industries.